泌尿器科学

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Prostatic Neoplasms 72%
3. Urinary Bladder Neoplasms 58%
4. Nephroureterectomy 46%
5. Neoplasms 46%
6. Carcinoma 43%
7. Recurrence 31%
8. Castration 31%
9. Prostate-Specific Antigen 25%
10. Kidney 24%
11. Survival 24%
12. Prostatectomy 23%
13. Neoplasm Metastasis 22%
14. Therapeutics 20%
15. Nephrectomy 19%
16. Prostate 19%
17. Japan 15%
18. cabazitaxel 15%
19. Adrenalectomy 15%
20. Urinary Bladder 14%
21. Axitinib 14%
22. Drug Therapy 13%
23. Cystectomy 12%
24. Androgens 12%
25. Docetaxel 12%
26. Cisplatin 11%
27. Sunitinib 11%
28. Urinary Tract 10%
29. Nivolumab 10%
30. Bacillus 10%
31. Sorafenib 9%
32. Tomography 9%
33. Survival Rate 9%
34. Safety 9%
35. Multivariate Analysis 8%
36. Biopsy 8%
37. dehydroxymethylepoxyquinomicin 8%
38. Brachytherapy 8%
39. Neoplasm Grading 8%
40. Progression-Free Survival 7%
41. Hydronephrosis 7%
42. Ureter 7%
43. Renal Dialysis 7%
44. Biomarkers 6%
45. Platinum 6%
46. Lymph Nodes 6%
47. Angiomyolipoma 6%
48. Urologic Neoplasms 6%
49. Aldosterone 6%
50. Interleukin-2 6%
51. Ureteral Obstruction 6%
52. Kidney Neoplasms 6%
53. Angiotensin Type 1 Receptor 6%
54. Genes 6%
55. C-Reactive Protein 6%
56. Molecular Targeted Therapy 6%
57. Apoptosis 6%
58. Lymph Node Excision 6%
59. Urologists 5%
60. Serum 5%
61. Operative Time 5%
62. pembrolizumab 5%
63. gemcitabine 5%
64. Lung 5%
65. Pneumoperitoneum 5%
66. Magnetic Resonance Imaging 5%
67. Incidence 5%
68. Ultrasonography 5%
69. Pheochromocytoma 5%
70. Prostatic Hyperplasia 5%
71. Radiotherapy 5%
72. Retrospective Studies 5%
73. Urine 5%
74. Intra-Abdominal Fat 5%
75. Hematuria 5%
76. Nomograms 5%
77. Interferons 5%
78. Carcinoma in Situ 5%
79. Dutasteride 5%